Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Gross Profit | -140,000 | 0% |
| Cost of Revenue | 140,000 | 0% |
| Operating expense | 43M | 13% |
| Net Income | -41M | 15.4% |
| EBITDA | -41M | 9.7% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 195M | 11.4% |
| Total Liabilities | 27M | 46.3% |
| Total Equity | 168M | 16.7% |
| Shares Outstanding | 89M | 4% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -25M | 36.6% |
| Cash from investing | 23M | 152.7% |
| Cash from financing | -31,000 | 100% |
EPS
Financial Highlights for Amylyx Pharmaceuticals in Q2 '25
Gross Profit stood at -140,000, marking a 0% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 140,000, a 0% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 43M, showing a 13% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -41M, showing a -15.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -41M, showing a -9.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Amylyx Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
